Ashley F. Ward

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

John C. Byrd, Stephen D. Smith, Nina D. Wagner‐Johnston et al. · Oncotarget · 2018 · 81 citations · Full text

Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group

Elliot Stieglitz, Ashley F. Ward, Robert B. Gerbing et al. · Pediatric Blood & Cancer · 2014 · 50 citations · Full text

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

Angell Shieh, Ashley F. Ward, Kegan Laureen Donlan et al. · Blood · 2013 · 28 citations · Full text

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Kelly J. Norsworthy, Flora Mulkey, Ashley F. Ward et al. · Blood · 2018 · 20 citations